首页 | 本学科首页   官方微博 | 高级检索  
     


Identification of novel peptide ligands for the cancer‐specific receptor mutation EFGRvIII using a mixture‐based synthetic combinatorial library
Authors:Charlotte Lund Denholt  Paul Robert Hansen  Nina Pedersen  Hans Skovgaard Poulsen  Nic Gillings  Andreas Kjær
Affiliation:1. Department of Nuclear Medicine and PET, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen ?, Denmark;2. Department of Natural Sciences, University of Copenhagen, 1871 Frederiksberg C, Denmark;3. The Department of Radiation Biology, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen ?, Denmark;4. Cluster for Molecular Imaging, University of Copenhagen, 2200 Copenhagen N, Denmark
Abstract:We report here, the design and synthesis of a positional scanning synthetic combinatorial library for the identification of novel peptide ligands targeted against the cancer‐specific epidermal growth factor tyrosine kinase receptor mutation variant III (EGFRvIII). This receptor is expressed in several kinds of cancer, in particular, ovarian, glioblastomas, and breast cancer, but not in normal tissue. The library consisted of six individual positional sublibraries in the format, H‐O1–6XXXXX‐NH2, O being one of the 19 proteinogenic amino acids (cysteine omitted) and X an equimolar mixture of these. The library consisted of 114 mixtures in total. Using a biotin‐streptavidin assay, the binding of each sublibrary to NR6M, NR6W‐A, and NR6 cells was tested. These cells express EGFRvIII, EGFR, and neither of the receptors, respectively. The result from each sublibrary was examined to identify the most active amino acid residue at each position. On the basis of this knowledge, eight peptides were synthesized and tested for binding to EGFRvIII. We identified one peptide, H‐FALGEA‐NH2, that showed more selective binding to the mutated receptor than the EGFRvIII specific peptide PEPHC1. This study demonstrates the value of using mixture‐based combinatorial positional scanning libraries for the identification of novel peptide ligands targeted against the cancer‐specific EGFRvIII. Our best candidate H‐FALGEA‐NH2 will be radioactively labeled and evaluated as an imaging agent for positron emission tomography investigation for diagnosis, staging, and monitoring of therapy of various types of cancer. © 2008 Wiley Periodicals, Inc. Biopolymers 91: 201–206, 2009. This article was originally published online as an accepted preprint. The “Published Online” date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at biopolymers@wiley.com
Keywords:cancer  combinatorial library  epidermal growth factor tyrosine kinase receptor mutation variant III (EGFRvIII)
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号